[Translated article] Alemtuzumab in relapsing–remitting multiple sclerosis in clinical practice: Annual NEDA-3 follow-up for up to 4 years
Alemtuzumab has proven to be effective, over 4 years, in clinical practice in patients with RRMS according to the different parameters of the NEDA-3 concept.
Authors
- García-Estévez Da
- Antonio Pato-Pato
- Maria Susana Fortes-González
- Martín Lorenzo-García
- Leticia Herrero-Poch
- Pablo Gaveiras-Araújo
- Jose Ramón Lorenzo-González
Institutions
- University Hospital Complex Of Vigo (ES)
- Complejo Hospitalario Universitario de Santiago (ES)
- Povisa Hospital (ES)
- Complejo Hospitalario de Ourense (ES)
Publication Details
- Journal
- Farmacia Hospitalaria
- Published
- 2026-02-01
- DOI
- https://doi.org/10.1016/j.farma.2025.12.005
- Primary Topic
- Multiple Sclerosis Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00